Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | SPX-303 |
| Trade Name | |
| Synonyms | SPX303|SPX 303 |
| Drug Descriptions |
SPX-303 is a bispecific antibody targeting LILRB2 and CD274 (PD-L1), which potentially enhances antitumor immune response and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 2729). |
| DrugClasses | LILRB2 Antibody 12 PD-L1/PD-1 antibody 133 |
| CAS Registry Number | NA |
| NCIT ID | C208071 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| SPX-303 | SPX-303 | 0 | 1 |